CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 243,002	$ 3,725,588
General and administrative	1,528,613	1,695,075
Total operating expenses	1,771,615	5,420,663
Loss before other income (expense)	(1,771,615)	(5,420,663)
Interest income, net and other	56,325	79,890
Loss from continuing operations	(1,715,290)	(5,340,773)
Net loss	$ (1,715,290)	$ (5,340,773)
Loss per common share, basic ( in dollar per share)	$ (0.41)	$ (2.23)
Loss per common share, diluted ( in dollar per share)	$ (0.41)	$ (2.23)
Weighted average number of shares outstanding, basic (in shares)	4,194,609	2,391,964
Weighted average number of shares outstanding, diluted (in shares)	4,194,609	2,391,964